Noliterax (Indapamide, Perindopril Arginine)

Indapamide and Perindopril arginine, the active ingredients in Noliterax, are a combination antihypertensive presented as an oral tablet for adult use. It treats hypertension by lowering blood pressure in patients who need reliable control. GNH USA supplies Noliterax as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Noliterax is indicated for the management of hypertension, a condition characterised by elevated arterial pressure. It works within the renin‑angiotensin‑aldosterone system and renal sodium handling pathways. - Essential hypertension: reduces systolic and diastolic blood pressure in patients with primary high blood pressure. - Secondary hypertension: assists in blood‑pressure control when hypertension is caused by an identifiable underlying condition. - Cardiovascular risk reduction: contributes to overall risk management in patients with hypertension and additional cardiovascular risk factors.

Noliterax may cause a range of adverse reactions, from mild to serious. Awareness of these effects helps clinicians monitor patients appropriately.

Common Side Effects: - Dizziness or light‑headedness, especially after the first dose. - Persistent dry cough. - Increased urinary frequency or volume. - Mild headache. - Electrolyte disturbances such as low potassium. - Fatigue or general weakness.

Serious or Rare Side Effects: - Angioedema involving face, lips, tongue or airway. - Severe hypotension leading to syncope. - Acute kidney injury or marked rise in serum creatinine. - Hyperkalemia with potentially life‑threatening cardiac effects. - Severe allergic reactions (e.g., Stevens‑Johnson syndrome).

Before initiating Noliterax, clinicians should evaluate patient history and monitor relevant parameters. - Renal function: assess baseline creatinine and eGFR, then monitor periodically. - Electrolytes: check serum potassium and sodium levels, especially in patients on other diuretics. - History of angioedema: avoid use in individuals with prior ACE‑inhibitor‑related swelling. - Pregnancy: use only if the potential benefit justifies the risk, as safety data are limited. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Noliterax can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Aliskiren in patients with diabetes or renal impairment: risk of severe hypotension and renal dysfunction. - Potassium‑sparing diuretics or supplements: may cause dangerous hyperkalemia. - Lithium: increased lithium concentrations leading to toxicity.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and impair renal function. - Other antihypertensives (beta‑blockers, calcium channel blockers): may enhance blood‑pressure lowering, requiring dose adjustments. - Diuretics other than indapamide: additive diuretic effect may cause volume depletion.